Logo image of ANEB

ANEBULO PHARMACEUTICALS INC (ANEB) Stock Fundamental Analysis

NASDAQ:ANEB - Nasdaq - US0345691036 - Common Stock - Currency: USD

1.18  -0.03 (-2.48%)

After market: 1.23 +0.05 (+4.24%)

Fundamental Rating

3

Taking everything into account, ANEB scores 3 out of 10 in our fundamental rating. ANEB was compared to 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ANEB as it has an excellent financial health rating, but there are worries on the profitability. ANEB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANEB has reported negative net income.
ANEB had a negative operating cash flow in the past year.
In the past 5 years ANEB always reported negative net income.
ANEB had a negative operating cash flow in each of the past 5 years.
ANEB Yearly Net Income VS EBIT VS OCF VS FCFANEB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ANEB has a Return On Assets of -48.40%. This is comparable to the rest of the industry: ANEB outperforms 40.40% of its industry peers.
ANEB's Return On Equity of -51.24% is in line compared to the rest of the industry. ANEB outperforms 54.04% of its industry peers.
Industry RankSector Rank
ROA -48.4%
ROE -51.24%
ROIC N/A
ROA(3y)-115.24%
ROA(5y)-105.79%
ROE(3y)-123.7%
ROE(5y)-111.36%
ROIC(3y)N/A
ROIC(5y)N/A
ANEB Yearly ROA, ROE, ROICANEB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ANEB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANEB Yearly Profit, Operating, Gross MarginsANEB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANEB has more shares outstanding
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANEB Yearly Shares OutstandingANEB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANEB Yearly Total Debt VS Total AssetsANEB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

ANEB has an Altman-Z score of 27.18. This indicates that ANEB is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 27.18, ANEB belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.18
ROIC/WACCN/A
WACCN/A
ANEB Yearly LT Debt VS Equity VS FCFANEB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 17.52 indicates that ANEB has no problem at all paying its short term obligations.
The Current ratio of ANEB (17.52) is better than 90.40% of its industry peers.
A Quick Ratio of 17.52 indicates that ANEB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 17.52, ANEB belongs to the top of the industry, outperforming 90.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.52
Quick Ratio 17.52
ANEB Yearly Current Assets VS Current LiabilitesANEB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

ANEB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ANEB will show a very strong growth in Earnings Per Share. The EPS will grow by 48.26% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.13%
EPS Next 2Y-43.94%
EPS Next 3Y-36.05%
EPS Next 5Y48.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANEB Yearly Revenue VS EstimatesANEB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 50M 100M 150M 200M
ANEB Yearly EPS VS EstimatesANEB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANEB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANEB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANEB Price Earnings VS Forward Price EarningsANEB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANEB Per share dataANEB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

ANEB's earnings are expected to decrease with -36.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.94%
EPS Next 3Y-36.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANEB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANEBULO PHARMACEUTICALS INC

NASDAQ:ANEB (5/1/2025, 8:45:05 PM)

After market: 1.23 +0.05 (+4.24%)

1.18

-0.03 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-14 2025-02-14/amc
Earnings (Next)05-08 2025-05-08
Inst Owners54.94%
Inst Owner Change-1.25%
Ins Owners40.54%
Ins Owner Change0%
Market Cap48.47M
Analysts82.86
Price Target8.16 (591.53%)
Short Float %0.19%
Short Ratio1.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.58%
Min EPS beat(2)-56.86%
Max EPS beat(2)-10.29%
EPS beat(4)2
Avg EPS beat(4)11.36%
Min EPS beat(4)-56.86%
Max EPS beat(4)62.44%
EPS beat(8)5
Avg EPS beat(8)12.03%
EPS beat(12)5
Avg EPS beat(12)-2.31%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)37.5%
EPS NY rev (1m)0%
EPS NY rev (3m)21.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB 3.24
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.4%
ROE -51.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-115.24%
ROA(5y)-105.79%
ROE(3y)-123.7%
ROE(5y)-111.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.52
Quick Ratio 17.52
Altman-Z 27.18
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y17.13%
EPS Next 2Y-43.94%
EPS Next 3Y-36.05%
EPS Next 5Y48.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.95%
OCF growth 3YN/A
OCF growth 5YN/A